The American Society for Clinical Oncology (ASCO) states that approximately 42,220 adults were suffering from primary liver cancer in the U.S. Out of those, an estimated 30,610 were men and 11,610 were women. ASCO further declared that since 1980, the rates of liver cancer have tripled. This information is published in an upcoming report by Fortune Business Insights, titled, “Liver Cancer Screening Market Size, Share and Global Trend By Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma), By Screening (Laboratory Testing, Imaging, Endoscopy, Biopsy), By End User (Hospitals, Oncology Clinics, Diagnostics Centers) and Geography Forecast till 2026.”
Browse Complete Report Details at
The report provides elaborate data regarding the global liver cancer screening market segmentation, followed by market share. Additionally, the report offers details about the latest developments happening in the industry. It further showcases in-depth information about ongoing trends and regional analysis.
Fortune Business Insights has listed some of the prominent market players operating in the liver cancer screening market. They are as follows:
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- Siemens Healthcare GmbH
- F. Hoffmann-La Roche Ltd
- Sysmex Corporation
- Biocept, Inc.
- Foundation Medicine, Inc.
- Other key market players
Rise in Demand for Preventive Care for Diagnostic Examinations to Favor Growth in North America
The global liver cancer screening market is geographically divided into the Middle East and Africa, North America, Asia Pacific, Europe, and Latin America. Amongst these, North America is in the dominant position and it currently holds the highest global cancer screening market share. The growth is attributed to the rising incidence of liver cancer, increasing demand for preventive care by diagnostic examinations, and high healthcare expenditure. Additionally, increasing awareness programs regarding liver cancer, easy access to advanced treatment options, increasing investments by key market players for the development of early diagnostic options, and well-established healthcare infrastructure are likely to fuel the liver cancer screening market growth in this region.
Asia Pacific, on the other hand, is considered to be one of the fastest-growing markets due to a rise in the prevalence of cancer. Moreover, expansion of healthcare infrastructure, greater disposable income, increasing demand for technologically advanced diagnostics, and high patient pool are expected to boost liver cancer screening market growth in this region.
Get Sample PDF Brochure at
Epigenomics and Oncimmune Aim to Increase Sales through Technologically Advanced Product Launches
The Johns Hopkins University of Johns Hopkins Health System Corporation announced that it received the biggest A Series investment for CancerSEEK in June 2019. CancerSEEK is a liquid biopsy test that is specially designed for detecting various cancer types at the initial stages of the disease. Thrive Earlier Detection Corp., a developer of cancer-detecting tests, based in Cambridge, is currently developing CancerSEEK with the help of $110 million funding. According to the company, CancerSEEK will be a blood-based test that would be cost-effective and would be used as part of regular medical care. The test will serve as a resource to support those patients and their families who are often confused and overwhelmed following a cancer diagnosis.
Epigenomics AG, a molecular diagnostics company, based in Berlin, announced the launch of its blood test called mSEPT9 in July 2018. In a clinical study, mSEPT9 exhibited more diagnostic accuracy than the already established diagnostic marker. It also surpassed alpha-fetoprotein (AFP), a widely used diagnostic marker. According to the company, an accurate blood test will have the capacity to monitor those patients who are at high risk for suffering from liver cancer.
Oncimmune Holdings plc, a cancer detection test provider, headquartered in the U.K., announced the launch of EarlyCDT-Liver test in May 2018. It would be used for hepatocellular carcinoma (HCC) and will be available commercially in the U.S. The test has a specificity of 97%. It is the second test delivered by Oncimmune after EarlyCDT-Lung test. The platform has the ability to detect cancer up to four years earlier. According to the company, the EarlyCDT-Liver test is complementary to diagnosis of cancer via imaging. It is a simple blood test. It further aids in early detection of HCC in patients. Overall, prominent key players are focusing on innovative product launches to gain competitive edge in the global cancer screening market.
Speak To Analyst at
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: [email protected]